rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Robert Nelsen

Director and 10% owner

Company insider

Files Form 4 as: Director and 10% owner, City Therapeutics; Director and 10% owner, Kardigan; Director and 10% owner, Prime Medicine; Director and 10% owner, Sana Biotechnology; Director and 10% owner, Lyell Immunopharma; 10% owner, Rapport Therapeutics; Director and 10% owner, Vir Biotechnology; 10% owner, Neumora Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
452
Buys
23
Sells
7
Bought
$150.7M
Sold
$20.7M
Companies
30
Companies where not an officer
30
First trade
18 May 2006
Last trade
19 Oct 2026
Last filed
19 Oct 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
CTY City TherapeuticsDirector, 10% owner · Biotechnology · last 19 Oct 20261 buy · 0 sells
KARD KardiganDirector, 10% owner · Biotechnology · last 22 Jun 20261 buy · 0 sells
PRME Prime MedicineDirector, 10% owner · Biotechnology · last 5 Jun 20263 buys · 0 sells
SANA Sana BiotechnologyDirector, 10% owner · Biotechnology · last 4 Jun 20261 buy · 0 sells
LYEL Lyell ImmunopharmaDirector, 10% owner · Biotechnology · last 14 Jun 20240 buys · 0 sells
RAPP Rapport Therapeutics10% owner · Biotechnology · last 10 Jun 20240 buys · 0 sells
VIR Vir BiotechnologyDirector, 10% owner · Biotechnology · last 30 May 20241 buy · 0 sells
NMRA Neumora Therapeutics10% owner · Biotechnology · last 29 Sep 20237 buys · 0 sells
DA32 Life Science Tech Acquisition10% owner · last 28 Jul 20230 buys · 0 sells
Verve Therapeutics10% owner · last 21 Jun 20210 buys · 0 sells
DNLI Denali TherapeuticsDirector, 10% owner · Biotechnology · last 2 Jun 20210 buys · 0 sells
Karuna TherapeuticsDirector, 10% owner · last 13 Apr 20211 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
19 Oct 2026filed 19 Oct 2026CTY City TherapeuticsBiotechnologySEC FORM 4 Code C—3,294,900filing
19 Oct 2026filed 19 Oct 2026CTY City TherapeuticsBiotechnologySEC FORM 4 Code C—5,482,309filing
19 Oct 2026filed 19 Oct 2026CTY City TherapeuticsBiotechnologySEC FORM 4 Code C—2,027,006filing
19 Oct 2026filed 19 Oct 2026CTY City TherapeuticsBiotechnologySEC FORM 4 Bought$3.1M170,000 at $18.00filing
19 Oct 2026filed 19 Oct 2026CTY City Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—3,000,000 at $0.00filing
19 Oct 2026filed 19 Oct 2026CTY City Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—4,991,633 at $0.00filing
19 Oct 2026filed 19 Oct 2026CTY City Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—1,845,585 at $0.00filing
15 Oct 2026filed 19 Oct 2026CTY City Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—22,649 at $0.00filing
22 Jun 2026filed 24 Jun 2026KARD KardiganBiotechnologySEC FORM 4 Bought$20.0M1,250,000 at $16.00filing
17 Jun 2026filed 22 Jun 2026KARD Kardiganoption or derivative · BiotechnologySEC FORM 4 Code C—5,148,587filing
17 Jun 2026filed 22 Jun 2026KARD Kardiganoption or derivative · BiotechnologySEC FORM 4 Code C—1,204,000filing
17 Jun 2026filed 22 Jun 2026KARD Kardiganoption or derivative · BiotechnologySEC FORM 4 Code C—2,306,401filing
17 Jun 2026filed 22 Jun 2026KARD KardiganBiotechnologySEC FORM 4 Code C—13,792,035filing
5 Jun 2026filed 8 Jun 2026PRME Prime Medicineoption or derivative · BiotechnologySEC FORM 4 Code A—75,000 at $0.00filing
5 Jun 2026filed 8 Jun 2026PRME Prime Medicineoption or derivative · BiotechnologySEC FORM 4 Code A—75,000 at $0.00filing
4 Jun 2026filed 5 Jun 2026SANA Sana Biotechnologyoption or derivative · BiotechnologySEC FORM 4 Code A—90,000 at $0.00filing
4 Jun 2026filed 5 Jun 2026SANA Sana Biotechnologyoption or derivative · BiotechnologySEC FORM 4 Code A—90,000 at $0.00filing
1 Aug 2025filed 5 Aug 2025PRME Prime Medicineoption or derivative · BiotechnologySEC FORM 4 Code D—39,062filing
1 Aug 2025filed 5 Aug 2025PRME Prime Medicineoption or derivative · BiotechnologySEC FORM 4 Code A—39,062filing
1 Aug 2025filed 5 Aug 2025PRME Prime Medicineoption or derivative · BiotechnologySEC FORM 4 Code D—45,000filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care23
Not placed7

Buys in green, sells in red, by the company’s sector.

Related people

ARCH Venture Partners XII, LLC10% owner · 10% owner at City Therapeutics, filing Form 4 there in the last year
Ron M. PhilipDirector · Director at City Therapeutics, filing Form 4 there in the last year
Barry E. GreeneDirector · Director at City Therapeutics, filing Form 4 there in the last year
John MaraganoreDirector · Director at City Therapeutics, filing Form 4 there in the last year
Andrew C. OrthPresident & CEO · President & CEO at City Therapeutics, filing Form 4 there in the last year
Adam LaponisChief Financial Officer · Also traded TWST in the last 90 days
Emily M. LeproustChief Executive Officer · Also traded TWST in the last 90 days
Dennis ChoOfficer · Also traded TWST in the last 90 days